KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Accured Expenses (2016 - 2026)

CRISPR Therapeutics AG (CRSP) has disclosed Change in Accured Expenses for 11 consecutive years, with $54.2 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 790.32% to $54.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.9 million through Dec 2025, up 264.55% year-over-year, with the annual reading at $44.9 million for FY2025, 264.55% up from the prior year.
  • Change in Accured Expenses hit $54.2 million in Q4 2025 for CRISPR Therapeutics AG, up from $802000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $54.2 million in Q4 2025 to a low of -$31.1 million in Q4 2022.
  • Historically, Change in Accured Expenses has averaged $2.0 million across 5 years, with a median of -$132000.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 16472.73% in 2023 and later plummeted 17210.0% in 2024.
  • Year by year, Change in Accured Expenses stood at $44.0 million in 2021, then plummeted by 170.68% to -$31.1 million in 2022, then soared by 36.8% to -$19.7 million in 2023, then soared by 60.05% to -$7.8 million in 2024, then soared by 790.32% to $54.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CRSP at $54.2 million in Q4 2025, $802000.0 in Q3 2025, and $443000.0 in Q2 2025.